Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir + emtricitabine
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
tenofovir + emtricitabine is a fixed-dose combination of two antiretroviral medications: tenofovir, a nucleotide reverse transcriptase inhibitor (NtRTI), and emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI). Distributed by Salud Pharma, this combination is indicated for the treatment of HIV-1 infection in adults and pediatric patients, typically as part of a multi-drug regimen, and for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk individuals. Both components work by competing with natural substrates for incorporation into viral DNA by the HIV reverse transcriptase enzyme, causing premature DNA chain termination and effectively halting viral replication. This combination is a cornerstone of modern antiretroviral therapy (ART) and PrEP programs globally.
- Brand names
- TruvadaDescovy
- Other names
- Tenofovir disoproxil fumarate + emtricitabineTenofovir alafenamide + emtricitabineTenofovir+Emtricitabina
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on tenofovir + emtricitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir + emtricitabine.